Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Receivables: 2023-2025

Historic Receivables for Krystal Biotech (KRYS) over the last 2 years, with Sep 2025 value amounting to $129.6 million.

  • Krystal Biotech's Receivables rose 33.23% to $129.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $449.1 million, marking a year-over-year increase of 29.31%. This contributed to the annual value of $104.7 million for FY2024, which is 149.16% up from last year.
  • Krystal Biotech's Receivables amounted to $129.6 million in Q3 2025, which was up 16.33% from $111.4 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Receivables registered a high of $129.6 million during Q3 2025, and its lowest value of $9.3 million during Q3 2023.
  • In the last 3 years, Krystal Biotech's Receivables had a median value of $103.3 million in 2025 and averaged $89.5 million.
  • As far as peak fluctuations go, Krystal Biotech's Receivables spiked by 944.42% in 2024, and later decreased by 1.38% in 2025.
  • Krystal Biotech's Receivables (Quarterly) stood at $42.0 million in 2023, then spiked by 149.16% to $104.7 million in 2024, then skyrocketed by 33.23% to $129.6 million in 2025.
  • Its last three reported values are $129.6 million in Q3 2025, $111.4 million for Q2 2025, and $103.3 million during Q1 2025.